MDRX Quote, Financials, Valuation and Earnings

LifeMD has a net margin of -- compared to Veradigm's net margin of -9.61%. Veradigm's return on equity of -- beat LifeMD's return on equity of --.

Veradigm has a consensus price target of --, signalling upside risk potential of 40.11%. On the other hand LifeMD has an analysts' consensus of $12.00 which suggests that it could grow by 139.23%. Given that LifeMD has higher upside potential than Veradigm, analysts believe LifeMD is more attractive than Veradigm.

Veradigm has a beta of 0.648, which suggesting that the stock is 35.152% less volatile than S&P 500. In comparison LifeMD has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.061%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. LifeMD pays out -15.08% of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than LifeMD quarterly revenues of $53.4M. Veradigm's net income of -- is lower than LifeMD's net income of -$5.1M. Notably, Veradigm's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.77x versus 1.01x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.

Oruka Therapeutics has a net margin of -- compared to Veradigm's net margin of --. Veradigm's return on equity of -- beat Oruka Therapeutics's return on equity of --.

Veradigm has a consensus price target of --, signalling upside risk potential of 40.11%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 252.38%. Given that Oruka Therapeutics has higher upside potential than Veradigm, analysts believe Oruka Therapeutics is more attractive than Veradigm.

Veradigm has a beta of 0.648, which suggesting that the stock is 35.152% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. Veradigm's net income of -- is lower than Oruka Therapeutics's net income of -$28.6M. Notably, Veradigm's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.77x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Streamline Health Solutions has a net margin of -- compared to Veradigm's net margin of -56.03%. Veradigm's return on equity of -- beat Streamline Health Solutions's return on equity of -54.79%.

Veradigm has a consensus price target of --, signalling upside risk potential of 40.11%. On the other hand Streamline Health Solutions has an analysts' consensus of $22.50 which suggests that it could fall by -59.89%. Given that Veradigm has higher upside potential than Streamline Health Solutions, analysts believe Veradigm is more attractive than Streamline Health Solutions.

Veradigm has a beta of 0.648, which suggesting that the stock is 35.152% less volatile than S&P 500. In comparison Streamline Health Solutions has a beta of 1.552, suggesting its more volatile than the S&P 500 by 55.205%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. Streamline Health Solutions pays out -- of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than Streamline Health Solutions quarterly revenues of $4.4M. Veradigm's net income of -- is lower than Streamline Health Solutions's net income of -$2.5M. Notably, Veradigm's price-to-earnings ratio is -- while Streamline Health Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.77x versus 0.79x for Streamline Health Solutions. Usually stocks with elevated PS ratios are considered overvalued.

TruBridge has a net margin of -- compared to Veradigm's net margin of -11.7%. Veradigm's return on equity of -- beat TruBridge's return on equity of -31.4%.

Veradigm has a consensus price target of --, signalling upside risk potential of 40.11%. On the other hand TruBridge has an analysts' consensus of $19.20 which suggests that it could fall by -12.78%. Given that Veradigm has higher upside potential than TruBridge, analysts believe Veradigm is more attractive than TruBridge.

Veradigm has a beta of 0.648, which suggesting that the stock is 35.152% less volatile than S&P 500. In comparison TruBridge has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.412%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. TruBridge pays out -- of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than TruBridge quarterly revenues of $83.8M. Veradigm's net income of -- is lower than TruBridge's net income of -$9.8M. Notably, Veradigm's price-to-earnings ratio is -- while TruBridge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.77x versus 0.97x for TruBridge. Usually stocks with elevated PS ratios are considered overvalued.